Literature DB >> 7386581

Operant conditioning of fusional convergence ranges using random dot stereograms.

J Cooper, J Feldman.   

Abstract

In Experiment 1, four 6- to 10-year-old strabismus patients, who had failed to improve convergence ranges using traditional vision training techniques, were given convergence training using random dot stereograms (RDS). An integral part of the RDS training procedure was the incorporation of an operant conditioning procedure providing for response-contingent positive reinforcement, immediate feedback, and preprogrammed systematic changes in convergence demand during discrimination learning. Findings indicated that operant RDS convergence training produced a significant increase in convergence ranges which transferred readily to vectogram tasks and resulted in a change from exotropia to exophoria for at least one patient. In Experiment 2, it was shown that improved convergence ability was a direct result of exposure to RDS of increasing convergence demand. It was concluded that young, uncooperative, language-deficient, or inattentive patients show improved convergence ranges when such training incorporates proper stimuli and the basic principles of learning and motivation into its training regimen.

Entities:  

Mesh:

Year:  1980        PMID: 7386581     DOI: 10.1097/00006324-198004000-00002

Source DB:  PubMed          Journal:  Am J Optom Physiol Opt        ISSN: 0093-7002


  2 in total

1.  Effectiveness of placebo therapy for maintaining masking in a clinical trial of vergence/accommodative therapy.

Authors:  Marjean Kulp; G Lynn Mitchell; Eric Borsting; Mitchell Scheiman; Susan Cotter; Michael Rouse; Susanna Tamkins; Brian G Mohney; Andrew Toole; Kathleen Reuter
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

2.  Diagnostic accuracy of indigenously developed computer-based binocular vision assessment.

Authors:  P Praveen Kumar; T Shajahan; Jameel Rizwana Hussaindeen
Journal:  Oman J Ophthalmol       Date:  2022-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.